Product Description
GlaxoSmithKline is developing GSK-2983559 as a treatment for inflammatory bowel diseases. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03358407)
Mechanisms of Action: RIPK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT03358407 | P1 |
Terminated |
Inflammatory Bowel Diseases |
2019-02-19 |
50% |
2020-06-23 |
Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/27/2023 |
PubMed |
OTUD1 ameliorates cerebral ischemic injury through inhibiting inflammation by disrupting K63-linked deubiquitination of RIP2. |
|
08/01/2023 |
PubMed |
Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease. |